CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)

2019-10-10 09:39:39 | BioPortfolio


CompARE is a multicentre, phase III open-label randomised controlled trial using an adaptive, Multi-Arm, Multi-Stage (MAMS) design.


The CompARE Trial examines alternative regimens for escalating treatment of intermediate and high-risk oropharyngeal cancer in an adult patient population. The aim is to assess whether escalated radiotherapy, adding surgery or immunotherapy will improve overall survival and quality of life in these patients.

Study Design


Oropharyngeal Cancer


Cisplatin, Durvalumab, Radiotherapy, Dose-escalated radiotherapy


Royal Devon and Exeter Hospital
United Kingdom




University of Birmingham

Results (where available)

View Results


Published on BioPortfolio: 2019-10-10T09:39:39-0400

Clinical Trials [2626 Associated Clinical Trials listed on BioPortfolio]

Cisplatin Plus Radiotherapy vs Durvalumab Plus Radiotherapy Followed by Durvalumab vs Durvalumab Plus Radiotherapy Followed by Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Oropharyngeal SCC

Sometimes, cancer patients receive an initial treatment, followed by additional treatment to lower the chance of cancer coming back. The standard or usual treatment for this type of diseas...

Adaptive Dose-Escalated Multi-modality Image-guided RadiothErapy

Patients with primary head and neck squamous cell carcinoma (HNSCC) planned for treatment with radiotherapy with or without chemotherapy in curative setting will be treated with an adaptiv...

Proton Based Cardiac Sparing Accelerated Fractionated RadioTherapy in Unresectable NSCLC

The purpose of this study is to treat participants with the combination of durvalumab (the study drug) and proton beam therapy. Proton beam therapy is a type of radiotherapy (RT) with a un...

BreAst Cancer and Cardiotoxicity Induced by RAdioTherapy: the BACCARAT Study

Breast radiotherapy RT used until the 1990s was clearly responsible for increased mortality due to long term cardiac complications. Since the 2000s, improvements have appeared in dose dist...

Dose Escalated Adaptive RadioTherapy in Definitive Chemo-radiotherapy for Esophageal Cancer

In Denmark, 1000 new cases of esophageal and gastro-esophageal junction cancer occur every year. Surgery is the primary treatment for patients with localized disease who are considered med...

PubMed Articles [18168 Associated PubMed Articles listed on BioPortfolio]

Sequencing of Androgen-Deprivation Therapy With External-Beam Radiotherapy in Localized Prostate Cancer: A Phase III Randomized Controlled Trial.

Dose-escalated radiotherapy (RT) with androgen-deprivation therapy (ADT) is a standard definitive treatment of localized prostate cancer (LPCa). The optimal sequencing of these therapies is unclear. O...

Fasting reduces intestinal radiotoxicity enabling dose-escalated radiotherapy for pancreatic cancer.

Chemotherapy combined with radiotherapy is the most commonly used approach for treating locally advanced pancreatic cancer. The use of curative doses of radiation in this disease setting is constraine...

Benefit of Cisplatin With Definitive Radiotherapy in Older Women With Cervical Cancer.

Cisplatin with definitive radiotherapy (RT) is considered the standard of care for cervical cancer; however, older women are frequently undertreated and have worse outcomes compared with younger patie...

Dose escalation study of amrubicin and cisplatin with concurrent thoracic radiotherapy for limited-disease small cell lung cancer.

Amrubicin and cisplatin is one of the active regimens used to treat patients with extensive-disease (ED)-small cell lung cancer (SCLC), whereas combined therapy involving chemotherapy and concurrent t...

"Dose of the day" based on cone beam computed tomography and deformable image registration for lung cancer radiotherapy.

Adaptive radiotherapy (ART) has potential to reduce toxicity and facilitate safe dose escalation. Dose calculations with the planning CT deformed to cone beam CT (CBCT) have shown promise for estimati...

Medical and Biotech [MESH] Definitions

Radiotherapy where there is improved dose homogeneity within the tumor and reduced dosage to uninvolved structures. The precise shaping of dose distribution is achieved via the use of computer-controlled multileaf collimators.

Radiotherapy given to augment some other form of treatment such as surgery or chemotherapy. Adjuvant radiotherapy is commonly used in the therapy of cancer and can be administered before or after the primary treatment.

CONFORMAL RADIOTHERAPY that combines several intensity-modulated beams to provide improved dose homogeneity and highly conformal dose distributions.

The total amount of radiation absorbed by tissues as a result of radiotherapy.

Radiotherapy where cytotoxic radionuclides are linked to antibodies in order to deliver toxins directly to tumor targets. Therapy with targeted radiation rather than antibody-targeted toxins (IMMUNOTOXINS) has the advantage that adjacent tumor cells, which lack the appropriate antigenic determinants, can be destroyed by radiation cross-fire. Radioimmunotherapy is sometimes called targeted radiotherapy, but this latter term can also refer to radionuclides linked to non-immune molecules (see RADIOTHERAPY).

More From BioPortfolio on "CompARE: Escalating Treatment of Intermediate and High-risk Oropharyngeal Cancer (OPC)"

Quick Search

Relevant Topics

Clincial Trials
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...

Cancer Disease
Cancer is not just one disease but many diseases. There are more than 100 different types of cancer. Most cancers are named for the organ or type of cell in which they start - for example, cancer that begins in the colon is called colon cancer; cancer th...

Searches Linking to this Trial